QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Leverages Subsidiaries To Support Research 0 comments
    May 8, 2013 5:36 PM | about stocks: ISCO

    One of the biggest challenges of taking a great new technology to market is funding, especially in the early stages of a developing company. Without a source of dependable money, research and development dies on the vine, before it gets a chance to play a potentially major role in the marketplace.

    International Stem Cell Corporation, doing research into the application of proprietary parthenogenetic stem cells in the treatment of diseases, has gone a long way toward addressing the problem of funding through two critical subsidiaries, Lifeline Cell Technology and Lifeline Skin Care. Together the subsidiaries generate the bulk of the company's revenue, which in turn help support important research and development efforts.

    But the two companies also have significant technological links to the parent company through their work with stem cells. Parthenogenetic stem cells were developed by ISCO to significantly advance the field of regenerative medicine by addressing the problem of immune-rejection. Parthenogenetic stem cells are true pluripotent stem cells, but are generated without the use of a fertilized human embryo. Not only does this avoid common ethical issues, it also means that the generated stem cells are much less likely to face immune matching problems that have long plagued stem cell application.

    Lifeline Cell Technology is an industry leader in the development and production of purified primary human cells and reagents for cell culture. They continue to make new and improved human cell systems and are making breakthroughs in the development of human stem cell products. In conjunction with this, the company conducts human cell in vitro research, development, and production at the ISCO facility in California.

    Lifeline Skin Care, provider of a powerful compound for regenerating skin cells, also works closely with ISCO, allowing it to offer the only products in the world that contain human, non-embryonic stem cell extracts. ISCO is the only source for these ground-breaking stem cell skin creams that can rejuvenate skin by actually helping to build new skin cells.

    For additional information, visit InternationalStemCell.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.